Finoriq research workspace
AMARIN CORP PLC\UK (AMRN) SEC Filings & Filing Highlights
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization. Review AMRN SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
- Company
- AMARIN CORP PLC\UK (AMRN)
- Ticker
- AMRN
- Market Cap
- $285.8M
- Latest Price
- $13.63
- Industry
- Biotech & Pharma
AMARIN CORP PLC\UK (AMRN) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for AMARIN CORP PLC\UK (AMRN).
| Event | Form | Date |
|---|---|---|
| • the reelection of Patrice Bonfiglio, Keith Horn, Odysseas Kostas, Louis Sterling, III and Dia...On May 13, 2026, Amarin Corporation plc (the “Company”) held its Annual General Meeting of Shareholders (the “Annual Meeting”). On the last... | 8-K5.07 | 2026-05-15 |
| Amarin Reports 2026 First Quarter Financial ResultsAmarin Reports 2026 First Quarter Financial Results | 8-K2.02 | 2026-04-29 |
| Director Resignations As part of its ongoing consideration of best corporate governance practic...Director Resignations As part of its ongoing consideration of best corporate governance practices, the Board of Directors (the “Board”) of... | 8-K5.02 | 2026-03-27 |
| Amarin Reports Fourth Quarter and Full Year 2025 Financial ResultsAmarin Reports Fourth Quarter and Full Year 2025 Financial Results | 8-K2.02 | 2026-02-25 |
| U.S. IPE Market Leadership Sustained; $70M Restructuring OPEX Savings on Pace for Mid-2026; Com...AMARIN ANNOUNCES PRELIMINARY 2025 FINANCIAL HIGHLIGHTS AND OPERATIONAL ACCOMPLISHMENTS, INCLUDING ACHIEVING POSITIVE CASH FLOW; COMPANY WEL... | 8-K2.02 | 2026-01-08 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.